Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Momentum in weight-loss drugs is the main reason why Eli Lilly's stock soared in 2025. Over the last five years it is up 459%, and that is excluding dividends. It is the largest drugmaker in the world ...

Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...